Capricor Therapeutics Inc. (CAPR)
CAPR trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1133869/000110465926029580/0001104659-26-029580-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | CAPR on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001133869 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$105.0M |
| Operating income | -$108.1M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | -100.0% |
| Cash | $287.8M |
| Total assets | $355.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-10 |
| Cash and burn | $44.3M cash; operating cash flow -$30.0M a quarter. | Report 2026-09-30 |
| Shares outstanding | 58,142,114 (2026-11-09); 45,718,475 a year earlier; 30,792,869 three years earlier. | Cover page 2026-11-09 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2025-12-05 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Rose, Snyder & Jacobs LLP, Encino, California, United States | PCAOB Form AP 2026-03-18 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $6.8M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$42.7M | -$35.7M | $44.3M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q2 2026 2026-06-30 | Not filed | -$40.7M | -$31.5M | $20.9M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q1 2026 2026-03-31 | Not filed | -$33.9M | -$29.3M | $105.4M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q4 2025 2025-12-31 | Not filed | -$30.2M | -$23.6M | $287.8M | No debt tags | $0 | 10-K 2026-03-17 |
| Q3 2025 2025-09-30 | Not filed | -$24.6M | -$19.7M | $19.5M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q2 2025 2025-06-30 | Not filed | -$25.9M | -$20.1M | $23.2M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q1 2025 2025-03-31 | Not filed | -$24.4M | -$6.4M | $28.8M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q4 2024 2024-12-31 | $11.1M | -$7.1M | -$14.8M | $11.3M | No debt tags | $22.3M | 10-K 2026-03-17 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-12-05 |
| Latest annual report | 10-K | 2026-03-17 |
| Latest quarterly / interim | 10-Q | 2026-11-10 |
| Latest current report | 8-K | 2026-11-10 |
| Latest proxy | DEF 14A | 2026-04-10 |
Source: SEC EDGAR submissions feed, 967 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +5.9% |
| 1 month | +38.5% |
| 3 months | +126.4% |
| Year to date | -67.0% |
| 1 year | +65.2% |
| From 52-week high | -73.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| NGNE | Neurogene Inc. Common Stock | $23.30 | -2.63% | $482.3M |
| PHAT | Phathom Pharmaceuticals Inc. | $5.88 | -2.97% | $478.0M |
| MNPR | Monopar Therapeutics Inc. | $71.97 | -0.04% | $487.7M |
| STTK | Shattuck Labs Inc. | $4.66 | +0.21% | $474.6M |
| AQST | Aquestive Therapeutics Inc. | $3.76 | -3.84% | $472.6M |
| OCS | Oculis Holding AG | $7.63 | -0.13% | $469.9M |
| LYEL | Lyell Immunopharma Inc. | $14.65 | +2.45% | $469.0M |
| KMDA | Kamada Ltd. | $8.11 | +0.25% | $468.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier